FDA approves high dose version of Novo Nordisk’s obesity drug Wegovy
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark,…
Biotech is resistant to AI disruption. Josh Brown likes these two stocks in the industry
(This is The Best Stocks in the Market , brought to you by Josh Brown and Sean Russo…
Eli Lilly’s lead in the obesity race gets wider after win against Novo
In the lucrative obesity drug race, there is Eli Lilly — and then there’s everybody else. A pair…
Alphabet capex plans spook investors, while AMD has a brutal day in markets
Signage outside the Google headquarters in Mountain View, California, US, on Tuesday, Feb. 3, 2026. David Paul Morris…
Another alliance of health care and AI signals why pharma stocks could be back
Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the…
I talked to many health CEOs out West and see big things for drug stocks
We get so caught up in the buzz and the sizzle that we forget about the steak, especially…
What to expect from pharma at the JPM conference
Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of…
What may be driving Eli Lilly shares lower — plus, oil, financial stocks rally
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Metsera Weight-Loss Drug Shows ‘Excellent’ Tolerability in Study
Metsera Inc.’s next-generation weight-loss drug showed good tolerability with few participants dropping out of a mid-stage trial, adding…
What’s next for the weight loss drug market: pills, rivals, insurance
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy,…
Trump pharmaceutical tariff threat lessens after Pfizer deal
U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla (L) as he announces a deal with…
Global Thyroid Gland Disorder Treatment Market to Increase at a Steady Growth Rate of ~3% by 2032
To read more about the latest highlights related to the thyroid gland disorder treatment market, get a snapshot…